Inozyme Pharma Inc (NAS:INZY)
$ 5.77 0.31 (5.68%) Market Cap: 356.90 Mil Enterprise Value: 216.98 Mil PE Ratio: 0 PB Ratio: 3.01 GF Score: 40/100

Inozyme Pharma Inc ENPP1 Deficiency Program Update Call Transcript

Jul 26, 2023 / 12:00PM GMT
Release Date Price: $5.5 (-10.86%)
Stefan Riley
Inozyme Pharma, Inc. - IR

Good morning and thank you for joining us for ENPP1 Deficiency Program update call. Before we begin our formal remarks, I would like to point you to our forward-looking statements disclaimer. I would like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in the company's recent filings with the Securities and Exchange Commission, which we urge you to read.

We undertake no obligation to update or revise any forward-looking statements to reflect new information or future events, except as required by law. Our actual results may differ materially from what is discussed on today's call. I would now like to turn the conference over to Douglas Treco, Chief Executive Officer, and Chairman of the Board of Directors of Inozyme Pharma. Please go ahead.

Douglas Treco
Inozyme Pharma, Inc. - CEO & Chairman of Board of Directors

Thank you, Stefan. At Inozyme, we're developing transformative therapies for rare

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot